Abstract
An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 μg TNF and 40 μg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24–26°C, anti-tumour effects were lost, whereas temperatures of 38–39°C or 42–43°C resulted in higher response rates. However, at 42–43°C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 μg in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38°C was mandatory. Moreover, the dose of TNF could be lowered to 10 μg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings. © 1999 Cancer Research Campaign
Keywords: TNF, melphalan, isolated limb perfusion, rats
Full Text
The Full Text of this article is available as a PDF (100.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexander H. R., Jr, Bartlett D. L., Libutti S. K., Fraker D. L., Moser T., Rosenberg S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998 Apr;16(4):1479–1489. doi: 10.1200/JCO.1998.16.4.1479. [DOI] [PubMed] [Google Scholar]
- Asher A., Mulé J. J., Reichert C. M., Shiloni E., Rosenberg S. A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987 Feb 1;138(3):963–974. [PubMed] [Google Scholar]
- Benckhuijsen C., Kroon B. B., van Geel A. N., Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol. 1988 Apr;14(2):157–163. [PubMed] [Google Scholar]
- Borel Rinkes I. H., de Vries M. R., Jonker A. M., Swaak T. J., Hack C. E., Nooyen P. T., Wiggers T., Eggermont A. M. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br J Cancer. 1997;75(10):1447–1453. doi: 10.1038/bjc.1997.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brouckaert P., Libert C., Everaerdt B., Fiers W. Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res. 1992 Aug;11(4):193–196. [PubMed] [Google Scholar]
- Clark J., Grabs A. J., Parsons P. G., Smithers B. M., Addison R. S., Roberts M. S. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res. 1994 Dec;4(6):365–370. doi: 10.1097/00008390-199412000-00004. [DOI] [PubMed] [Google Scholar]
- Eggermont A. M., Schraffordt Koops H., Klausner J. M., Kroon B. B., Schlag P. M., Liénard D., van Geel A. N., Hoekstra H. J., Meller I., Nieweg O. E. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996 Dec;224(6):756–765. doi: 10.1097/00000658-199612000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eggermont A. M., Schraffordt Koops H., Liénard D., Kroon B. B., van Geel A. N., Hoekstra H. J., Lejeune F. J. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996 Oct;14(10):2653–2665. doi: 10.1200/JCO.1996.14.10.2653. [DOI] [PubMed] [Google Scholar]
- Eggermont A. M. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv. 1996;26:335–349. [PubMed] [Google Scholar]
- Engelberts I., Möller A., Schoen G. J., van der Linden C. J., Buurman W. A. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res. 1991 Apr;10(1-2):69–76. [PubMed] [Google Scholar]
- Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D., Allison A. C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992 Mar;140(3):539–544. [PMC free article] [PubMed] [Google Scholar]
- Fraker D. L., Alexander H. R., Andrich M., Rosenberg S. A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996 Feb;14(2):479–489. doi: 10.1200/JCO.1996.14.2.479. [DOI] [PubMed] [Google Scholar]
- Fraker D. L., Alexander H. R., Thom A. K. Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock. 1994 Sep;44(1):45–50. [PubMed] [Google Scholar]
- Hill S., Fawcett W. J., Sheldon J., Soni N., Williams T., Thomas J. M. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg. 1993 Aug;80(8):995–997. doi: 10.1002/bjs.1800800820. [DOI] [PubMed] [Google Scholar]
- Klaase J. M., Kroon B. B., Benckhuijsen C., van Geel A. N., Albus-Lutter C. E., Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer. 1989 Aug 1;64(3):616–621. doi: 10.1002/1097-0142(19890801)64:3<616::aid-cncr2820640309>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
- Klostergaard J., Leroux E., Siddik Z. H., Khodadadian M., Tomasovic S. P. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res. 1992 Oct 1;52(19):5271–5277. [PubMed] [Google Scholar]
- Kramer S. M., Carver M. E. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods. 1986 Nov 6;93(2):201–206. doi: 10.1016/0022-1759(86)90189-4. [DOI] [PubMed] [Google Scholar]
- Krementz E. T., Carter R. D., Sutherland C. M., Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977 May;185(5):555–564. doi: 10.1097/00000658-197705000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lienard D., Ewalenko P., Delmotte J. J., Renard N., Lejeune F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992 Jan;10(1):52–60. doi: 10.1200/JCO.1992.10.1.52. [DOI] [PubMed] [Google Scholar]
- Manusama E. R., Nooijen P. T., Stavast J., Durante N. M., Marquet R. L., Eggermont A. M. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996 Apr;83(4):551–555. doi: 10.1002/bjs.1800830438. [DOI] [PubMed] [Google Scholar]
- Niitsu Y., Watanabe N., Umeno H., Sone H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res. 1988 Feb 1;48(3):654–657. [PubMed] [Google Scholar]
- Nooijen P. T., Eggermont A. M., Verbeek M. M., Schalkwijk L., Buurman W. A., de Waal R. M., Ruiter D. J. Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):33–44. doi: 10.1097/00002371-199601000-00004. [DOI] [PubMed] [Google Scholar]
- Nooijen P. T., Manusama E. R., Eggermont A. M., Schalkwijk L., Stavast J., Marquet R. L., de Waal R. M., Ruiter D. J. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer. 1996 Dec;74(12):1908–1915. doi: 10.1038/bjc.1996.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Omlor G., Gross G., Ecker K. W., Burger I., Feifel G. Optimization of isolated hyperthermic limb perfusion. World J Surg. 1992 Nov-Dec;16(6):1117–1119. doi: 10.1007/BF02067073. [DOI] [PubMed] [Google Scholar]
- Renard N., Liénard D., Lespagnard L., Eggermont A., Heimann R., Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer. 1994 Jun 1;57(5):656–663. doi: 10.1002/ijc.2910570508. [DOI] [PubMed] [Google Scholar]
- Renard N., Nooijen P. T., Schalkwijk L., De Waal R. M., Eggermont A. M., Liénard D., Kroon B. B., Lejeune F. J., Ruiter D. J. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol. 1995 Jul;176(3):279–287. doi: 10.1002/path.1711760310. [DOI] [PubMed] [Google Scholar]
- Robins H. I., d'Oleire F., Kutz M., Bird A., Schmitt-Tiggelaar C. L., Cohen J. D., Spriggs D. R. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia. Cancer Lett. 1995 Feb 10;89(1):55–62. doi: 10.1016/0304-3835(95)90158-2. [DOI] [PubMed] [Google Scholar]
- Scheringa M., Keizer A., Jeekel J., Marquet R. L. Anti-tumor effect of recombinant murine TNF-alpha (rMuTNFa) given by continuous i.v. infusion as compared to repeated i.v. injections in a rat liver metastasis model. Int J Cancer. 1989 May 15;43(5):905–909. doi: 10.1002/ijc.2910430529. [DOI] [PubMed] [Google Scholar]
- Scott R. N., Kerr D. J., Blackie R., Hughes J., Burnside G., MacKie R. M., Byrne D. S., McKay A. J. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer. 1992 Jul;66(1):159–166. doi: 10.1038/bjc.1992.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skarsgard L. D., Skwarchuk M. W., Vinczan A., Kristl J., Chaplin D. J. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res. 1995 Jan-Feb;15(1):219–223. [PubMed] [Google Scholar]
- Thompson J. F., Gianoutsos M. P. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 1992 Mar-Apr;16(2):227–233. doi: 10.1007/BF02071525. [DOI] [PubMed] [Google Scholar]
- Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989 Dec 1;49(23):6449–6465. [PubMed] [Google Scholar]
- Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988 Apr 15;48(8):2179–2183. [PubMed] [Google Scholar]
- Watanabe N., Niitsu Y., Umeno H., Sone H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 1988 Feb 1;48(3):650–653. [PubMed] [Google Scholar]
- Wu Z. Y., Smithers B. M., Parsons P. G., Roberts M. S. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer. 1997;75(8):1160–1166. doi: 10.1038/bjc.1997.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Vries M. R., Borel Rinkes I. H., van de Velde C. J., Wiggers T., Tollenaar R. A., Kuppen P. J., Vahrmeijer A. L., Eggermont A. M. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res. 1998;147:107–119. doi: 10.1007/978-3-642-80460-1_11. [DOI] [PubMed] [Google Scholar]